Off-Label Use of Biologics for IMIDs
![](https://jdnppa.com/wp-content/uploads/2021/02/Boh_preroll.001.jpeg)
Dr. Erin Boh says understanding disease pathophysiology provides treatment option insights for immune mediated inflammatory diseases that do not have FDA-approved therapies. According to dermatologist Erin E. Boh, MD, PhD, understanding disease pathophysiology is key to treating immune mediated inflammatory diseases (IMIDs) that do not have efficacious, FDA-approved therapies. In her presentation, “Off Label Use […]